The Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG) Network will issue a request for proposals (RFP) for data requests with a submission deadline of September 30th, 2024. The RFP will be open to investigators at REPRIEVE sites (both ACTG and REPRIEVE protocol specific sites). At the current time, this request is limited to data, including clinical data and currently available biomarker data. See below for the REPRIEVE protocol, which contains a schedule of evaluations, baseline characteristics of REPRIEVE participants and available clinical outcomes, dataset availability, and biomarker availability. Requests for samples may be considered in a future RFP.

The ACTG Comorbidities Transformative Science Group (CTSG) will coordinate the first round of reviews to ensure a wide range of expertise is available and that proposals fall within the interest and scope of the ACTG and REPRIEVE Leadership. Proposals reviewed by the ACTG should include a brief statistical plan that references the available datasets provided below. If there are overlapping proposals submitted, investigators with such proposals will be contacted by the ACTG to facilitate collaboration.

After initial review by the ACTG CTSG, a select number of scientifically relevant proposals will be forwarded by the ACTG CTSG to the REPRIEVE Publications Committee for review. The REPRIEVE Publications Committee will select up to 10 meritorious proposals based on scientific importance, availability of data, nonoverlap with any current or planned proposals, feasibility, and robustness of the statistical plan. Decisions will be announced in early 2025. Depending on data availability and resources, subsequent RFP’s may be issued for REPRIEVE data. Highly ranked projects not accepted in the first RFP may be resubmitted in a subsequent RFP for REPRIEVE data sharing. The REPRIEVE Publications SOP outlines requirements and next steps for subsequent manuscript development.

A list of projects approved and under development by the REPRIEVE team is presented below. These projects largely represent prespecified Aims of the original REPRIEVE grant, supplementally funded Aims, and/or planned investigations of relevant areas of interest. Please review this list to ensure that there is not overlap with an ongoing REPRIEVE project. Proposals submitted through this RFP for projects already underway cannot be approved. However, REPRIEVE will continue to solicit interest and create opportunities for site investigators to join the authorship teams of existing projects. 

Authorship: The lead author will submit a list of potential co-authors based on contribution and/or planned contribution with the initial proposal to the ACTG. For accepted proposals, at least one REPRIEVE Chair and Vice Chair and additional co-authors (based on contribution to the main trial, expertise, and equitable sharing of opportunities) will be assigned to each proposal and subsequent manuscripts. The final list of authors and author order will be approved by the REPRIEVE Publications and Executive Committee. All authors must meet ICMJE authorship requirements. Further details about authorship can be found in the REPRIEVE Publications SOP.

Budget: Writing teams must pursue their own sources of statistical funding and outline that source in the proposal. If the proposal requests analysis support by the REPRIEVE statistical core, the proposed effort, sources of support and methodologies to be used for this analysis must be outlined. If a proposal is under consideration for approval, proposers will be given an opportunity to estimate statistical effort with the REPRIEVE statistical core. If a statistical analysis is to occur outside the REPRIEVE statistical core, the analysis and proposed statistical team must be approved by the REPRIEVE statistical core, with sources of support outlined.

Click herto submit a proposal to the ACTG CTSG for review

Click here for the REPRIEVE protocol

Click here for the REPRIEVE Manual of Procedures (MOPs)

Click here for the REPRIEVE Publications Standard Operating Procedures (SOP)

Click here for a list of available labs and biomarkers

Click here for a list of biomarkers currently undergoing analysis in the REPRIEVE substudy (A5333s)

Click here for a list of baseline characteristics of REPRIEVE participants and available clinical outcomes

Click here for a list of the REPRIEVE analysis datasets

Current Projects Approved and Under Development by the REPRIEVE Team*

*Additional projects may be in the planning stage by the REPRIEVE Team.

Click here to learn about the REPRIEVE Ancillary Studies

REPRIEVE Main Study (A5332)

  • Performance of the ACC/AHA Pooled Cohort Equations in REPRIEVE and Recalibration
    Lead Author(s): Steve Grinspoon, Markella Zanni, Pamela Douglas
  • Prognostic Factors of Major Adverse Cardiovascular Events
    Lead Author(s): Markella Zanni, Steve Grinspoon
  • Statin Effects on Non-CVD Endpoints/Non-Adjudicated Events (START Endpoint)
    Lead Author(s): Triin Umbleja, Marissa Diggs
  • Effects of Antiretroviral Therapy Exposure (Never/Former/Current) on Major Adverse Cardiovascular Events
    Lead Author(s): Carl Fichtenbaum, Carlos Malvestutto
  • Effects of NRTI (Abacavir, TDF, TAF) on Major Adverse Cardiovascular Events
    Lead Author(s): Carl Fichtenbaum, Carlos Malvestutto, Emma Davies Smith
  • Predictors of Incident Diabetes and Statin Effects
    Lead Author(s): Kathleen Fitch, Steve Grinspoon
  • Statin Effects on COVID-19 Outcomes
    Lead Author(s): Markella Zanni, Triin Umbleja
  • Statin Effects on Cognitive Function in REPRIEVE and HAILO
    Lead Author(s): Kristine Erlandson
  • Effects of INSTIs on Blood Pressure and the Mediating Effects of Kidney Function and BMI
    Lead Author(s): Alana Brennan, Emma Kileel, Jen Manne-Goehler
  • Cost and Cost-Effectiveness of Pitavastatin to Prevent Cardiovascular Disease in People with HIV
    Lead Author(s): Thomas Mayrhofer, Michael Lu
  • Analysis of a Frailty Index in REPRIEVE
    Lead Author(s): Ariela Orkaby, Alan Landay, George Kuchel, Kristine Erlandson
  • Global Burden of Disease Effects on Major Adverse Cardiovascular Events
    Lead Author(s): Gerald Bloomfield, Pamela Douglas
  • Heart Failure and Heart Failure Risk Factors in REPRIEVE
    Lead Author(s): Gerald Bloomfield, Pamela Douglas
  • Mechanisms of Pitavastatin Effects: LDL vs. inflammation
    Lead Author(s): Steve Grinspoon, Pamela Douglas
  • Statin Effects and Role of Other Lipids in Cardiovascular Disease: TGL, HDL, lp(a)
    Lead Author(s): Steve Grinspoon, Pradeep Natarajan
  • Predictors of Weight Change and INSTI Effects
    Lead Author(s): Emma Kileel, Steve Grinspoon
  • Life's Essential 8 and Major Adverse Cardiovascular Events
    Lead Author(s): Pamela Douglas, Steve Grinspoon
  • Predictors of Myalgia in REPRIEVE
    Lead Author(s): Kristine Erlandson
  • Statin Effects on Cancer
    Lead Author(s): Steve Grinspoon
  • Sex Effects on Major Adverse Cardiovascular Events
    Lead Author(s): Markella Zanni
  • Personalized Prediction Effects of Statins
    Lead Author(s): Evelyne Zhang
  • EKG Predictors of Major Adverse Cardiovascular Events
    Lead Author(s): Gerald Bloomfield, Pamela Douglas

REPRIEVE Mechanistic Substudy (A5333s)

  • Health-Related Quality of Life and Atherosclerotic Cardiovascular Disease
    Lead Author(s): Marissa Diggs, Kathleen Fitch
  • Statin Effects on Transcriptomics and Related Outcomes (Plaque, Diabetes, Liver, and Others)
    Lead Author(s): Steve Grinspoon
  • Statin Effects on Pericoronary Fat Attenuation (PCAT) and Epicardial Fat
    Lead Author(s): Borek Foldyna
  • HIV, Cardiovascular Disease Risk and Coronary Atherosclerosis: A cross-country comparison between the United States and Uganda
    Lead Author(s): Mark Siedner, Brian Ghoshhajra
  • Epigenetic Aging in REPRIEVE
    Lead Author(s): Michael Corley, Alan Landay, Kristine Erlandson, Steve Grinspoon
  • REPRIEVE Mechanistic Substudy Biomarkers Analysis
    Lead Author(s): Michael Lu, Steve Grinspoon
  • Association Between Risk Factors, Inflammatory Markers and Coronary Atherosclerotic Radiomic Phenotypes in People with HIV
    Lead Author(s): Marton Kolossvary, Michael Lu
  • Proteomics Analysis of INSTI Use in REPRIEVE
    Lead Author(s): Marton Kolossvary, Emma Kileel
  • Plaque Presence, Progression, and MACE in the REPRIEVE Mechanistic Substudy
    Lead Author(s): Michael Lu, Steve Grinspoon
  • Individual Plaque Analyses in the REPRIEVE Mechanistic Substudy
    Lead Author(s): Michael Lu, Borek Foldyna, Thomas Mayrhofer, Heather Ribaudo
  • Statin Effects on Coronary Plaque Composition and Calcification
    Lead Author(s): Michael Lu, Borek Foldyna
  • Machine Learning Prediction of Coronary Plaque, Plaque Progression, and Major Adverse Cardiovascular Events
    Lead Author(s): Michael Lu
  • Computational Fluid Dynamics to Predict Coronary Plaque and Plaque Progression
    Lead Author(s): Michael Lu
  • Prognostic Factors of Plaque Progression
    Lead Author(s): Michael Lu
  • Aortic Plaque and Inflammation
    Lead Author(s): Michael Lu, TBD
  • Cardiac Morphology and Changes with Statins
    Lead Author(s): Michael Lu, Borek Foldyna
  • Lung Health and Inflammation with Statin Therapy
    Lead Author(s): Michael Lu, TBD
  • Incidental Findings on Cardiac CT in HIV
    Lead Author(s): Nina Meyersohn, Sandeep Hedgire, Michael Lu
  • Antiretroviral Therapy and Coronary Artery Plaque
    Lead Author(s): REPRIEVE Substudy Team
  • Longitudinal Analysis of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Lead Author(s): REPRIEVE Substudy Team
  • Effects of Sex Hormones on Coronary Artery Plaque
    Lead Author(s): Markella Zanni, Sara Looby

REPRIEVE Ancillary Studies

  • Proteinuria and Albuminuria in REPRIEVE: Prevalence and Associated Factors
    Lead Author(s): E Turner Overton
  • Statin Effects on Muscle Function and Frailty in PREPARE
    Lead Author(s): Kristine Erlandson
  • Statin Effects on Cardiac Structure and Function
    Lead Author(s): Tom Neilan, Markella Zanni
  • Longitudinal Analysis of Kidney Function in REPRIEVE
    Lead Author(s): E Turner Overton
  • Clonal Hematopoiesis of Indeterminate Potential and Major Adverse Cardiovascular Events
    Lead Author(s): Romit Bhattacharya, Aniruddh Patel, Pradeep Natarajan
  • Polygenic Risk Scores and Major Adverse Cardiovascular Events
    Lead Author(s): Aniruddh Patel, Roger Zou, Romit Bhattacharya, Pradeep Natarajan
  • Sex Differences in Statin-Induced Immunomodulation
    Lead Author(s): Markella Zanni, Sara Looby
  • Effects of Reproductive Aging vs. Chronologic Aging on ASCVD Events in Women
    Lead Author(s): Sara Looby, Markella Zanni
  • Genetics of Diabetes in REPRIEVE
    Lead Author(s): Luke Wander, Josep Mercader